Sanofi is developing a COVID-19 vaccine based on the traditional/proven recombinant-platform technology. It has the capability to manufacture 1bn doses by the end of 2021. Also, the French firm has joined hands with Translate Bio to develop a candidate using a new, though unproven, mRNA-technology – if successful, 400m doses would be ready by the end of 2021. As governments across the globe try to achieve herd immunity for their citizens, pre-booking for COVID-19 vaccines have already s
26 Jun 2020
Diagnosing Sanofi’s COVID-19 vaccine portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diagnosing Sanofi’s COVID-19 vaccine portfolio
Sanofi (SANO:WBO) | 0 0 1.3% | Mkt Cap: 81,283m
- Published:
26 Jun 2020 -
Author:
Rishabh Kochar -
Pages:
3
Sanofi is developing a COVID-19 vaccine based on the traditional/proven recombinant-platform technology. It has the capability to manufacture 1bn doses by the end of 2021. Also, the French firm has joined hands with Translate Bio to develop a candidate using a new, though unproven, mRNA-technology – if successful, 400m doses would be ready by the end of 2021. As governments across the globe try to achieve herd immunity for their citizens, pre-booking for COVID-19 vaccines have already s